Who the higher dose is for

Your prescriber may consider 7.2 mg, where needed, for adult weight management in obesity after at least four weeks on 2.4 mg weekly. The authorisation does not cover adolescents, the overweight-only weight-management group, the cardiovascular-risk indication or the MASH indication. Your prescriber must confirm both the indication and your individual circumstances fit.

You do not have to move to 7.2 mg. If you are doing well on 2.4 mg, you may have little reason to change. A plateau, a comparison on social media or the arrival of a stronger product does not justify the switch on its own.

Two ways to take the prescribed dose

Current product information allows one 7.2 mg injection with the dedicated device, or three 2.4 mg injections one after another, depending on the presentation prescribed. Both deliver the same total weekly amount. Never combine them.

The dedicated 7.2 mg pen is a single-dose device. The familiar lower-strength FlexTouch pen holds four doses. Read the instructions and disposal steps for the 7.2 mg pen on their own terms. If you are prescribed three injections, use a new needle for each and space injection sites at least 5 cm apart.

What the STEP UP trial found

In adults with obesity and without diabetes, the STEP UP treatment-policy analysis estimated average weight changes at 72 weeks of 18.7% with 7.2 mg, 15.6% with 2.4 mg and 3.9% with placebo. A second analysis, which assumed people kept taking treatment, estimated 20.7%, 17.5% and 2.4%. The two sets of figures answer different statistical questions.

Treat the larger headline figure as a trial average. Nobody can guarantee you that result in everyday life. The trial also does not prove every person who plateaus on 2.4 mg will gain the average extra benefit. How the dose was increased and who took part both matter when you apply the results to your own decision.

Side effects and practical trade-offs

Digestive side effects still matter. Changes in skin sensation, sometimes described as burning, tingling or unusual sensitivity, also stood out in the higher-dose research programme. Report new symptoms. Do not assume a symptom is harmless because the leaflet lists it.

Think about cost, supply format, the number of injections and how easily you can reach clinical support. A higher dose adds complexity when you travel or if the pharmacy switches between presentations. Get the total weekly amount confirmed in writing whenever you receive a new box or device.

Before your first 7.2 mg dose

Go through your current symptoms, food and fluid intake, other medicines and the exact date of your last injection with your prescriber. Ask what would lead to a pause, a lower dose or urgent assessment. Stop your previous 2.4 mg routine when the new regimen starts, unless your clinician's written plan uses 2.4 mg injections as the way to deliver 7.2 mg.

Regulatory authorisation does not guarantee NHS funding or pharmacy stock. Check both. If the supply differs from your prescription or the instructions are unclear, settle it with the dispensing team before you use it.

Sources

Your own medicine leaflet and prescriber come first. A source from another country does not mean the same rule applies in the UK.

  1. Wegovy FlexTouch UK prescribing information medicines.org.uk
  2. MHRA: single-dose 7.2 mg Wegovy pen approval gov.uk
  3. Wegovy 7.2 mg single-dose pen leaflet medicines.org.uk

Spotted something out of date? Report a mistake.